News Category
Regentis Biomaterials is developing GelrinC, an off-the-shelf hydrogel implant designed to regenerate knee cartilage, offering a potential alternative...
American Fusion Inc. has moved its Texatron fusion program into active testing, achieving 100,000 atmospheres of pressure, a critical step toward demo...
The article details the format and purpose of the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, emphasizing its focus on ...
SuzieQ Holdings' participation in the Moody Capital Solutions conference underscores its role in building the measurement and sovereignty layer for th...
A new study confirms that treating certain ER patients while seated instead of waiting for a bed can significantly reduce wait times, potentially lead...
Helus Pharma reported progress in its Phase 3 program for HLP003 in major depressive disorder, with enrollment completed and topline data expected in ...
Helus Pharma's appointment of Michael Halstead as CEO signals strategic preparation for commercialization as the company advances its lead candidate t...
Ocumetics Technology Corp. has completed a $2.5 million tranche of its private placement, bringing total proceeds to nearly $3 million to fund its inn...
Shareholders of VERAXA Biotech AG approved key corporate governance and financing measures, enhancing flexibility for growth and strategic initiatives...
VERAXA Biotech announced the advancement of its bispecific antibody-drug conjugate program VXA-222 after OmniAb completed discovery work, moving the p...
Gerresheimer has opened a new state-of-the-art plant in Zhenjiang Dagang, China, doubling its production capacity for glass primary pharmaceutical pac...
Darwin AG has officially changed its name to Novogenia AG, aligning its corporate identity with its core operating brand to enhance market visibility ...
NanoViricides progresses its oral gummies formulation of NV-387 toward a Phase II trial for the Bundibugyo ebolavirus outbreak in the DRC, where no ap...
Redwood AI Corp. has been included in the CSE25 Index, marking its status among the 25 largest companies on the Canadian Securities Exchange and poten...
Helus Pharma announced fiscal 2026 financial results and progress in its Phase 3 trial for major depressive disorder, with topline data expected in Q4...
Quantum BioPharma Ltd. is featured in a BioMedWire editorial highlighting its novel drug candidate Lucid-MS, which aims to repair myelin damage in mul...
The article explores how advanced drug delivery systems, such as Oncotelic Therapeutics' Deciparticle platform, are poised to revolutionize cancer tre...
Quantum BioPharma's Lucid-MS, a first-in-class neuroprotective drug candidate for multiple sclerosis, is progressing to Phase 2 trials after successfu...
VERAXA Biotech announced new in vitro data showing its BiTAC-ADC platform can selectively kill breast cancer cells while sparing healthy cells, valida...
Redwood AI Corp.'s proprietary AI platforms accelerate chemistry research and development, impacting pharmaceuticals, defense, public safety, and indu...
NanoViricides announced DRC approval to proceed with a Phase II trial of NV-387 Oral Gummies for Bundibugyo ebolavirus, marking a potential breakthrou...
Helus Pharma's participation in the H.C. Wainwright conference highlights its progress in developing novel serotonergic agonists for mental health con...
Onco-Innovations Limited has initiated process development and scale-up for its drug candidate ONC010, a key step toward IND-enabling studies and firs...
Quantum BioPharma Ltd. has completed Phase 1 clinical studies for LUCID-MS, a potential therapy targeting myelin repair in multiple sclerosis, and sub...
NeuroOne Medical Technologies will present at the Planet MicroCap Las Vegas 2026 Conference on June 17, 2026, providing commercialization updates and ...
GeoVax CEO comments on recent pharmaceutical acquisitions signaling a strategic shift toward vaccine innovation and health security amid escalating gl...
Quantum BioPharma's appearance on the BioMedWire Podcast underscores the potential of its lead drug candidate Lucid-MS for multiple sclerosis and its ...
Helus Pharma's participation in the Jefferies conference underscores its progress with HLP003, a Breakthrough Therapy-designated drug for major depres...
TransCode Therapeutics has started a Phase 2a trial of TTX-MC138 in colorectal cancer patients with minimal residual disease, aiming to reduce recurre...
NanoViricides announces that its broad-spectrum antiviral NV-387 warrants evaluation for the Bundibugyo Ebola outbreak due to its host-targeted mechan...
SureNano Science, through its acquisition of GlucaPharm, is advancing GEP-44, a novel GLP-1 peptide for obesity and metabolic disorders, targeting imp...
Oncotelic Therapeutics announces the integration of 28 million scientific abstracts into its PDAOAI platform, positioning itself to compete with big p...
Telomir Pharmaceuticals announced peer-reviewed preclinical data showing Telomir-Zn improved survival and reduced oxidative stress, hepatic copper, an...
Lantern Pharma announces FDA non-objection to protocol amendments for its Phase 2 HARMONIC trial of LP-300 in never-smokers with advanced NSCLC, clari...
NanoViricides emphasizes the potential of its oral drug candidate NV-387 as a broad-spectrum antiviral for Ebola and other filoviruses, positioning it...
Quantum BioPharma announced that patient enrollment in its collaborative MS imaging study with Massachusetts General Hospital has reached the halfway ...
LIXTE Biotechnology Holdings announced first-quarter 2026 progress, including expansion of its ovarian cancer trial for lead candidate LB-100 and grow...
Dogwood Therapeutics announced financial results for Q1 2026, highlighting progress in its pain and neuropathy pipeline with Phase 2b data for Halneur...
Advances in blood-brain barrier penetration, such as Oncotelic's intranasal nose-to-brain system, are poised to transform CNS drug development and cre...
Silo Pharma announced a strategic initiative to explore ibogaine-based therapeutics for traumatic brain injury and related conditions, filing a provis...
Three fatalities from hantavirus on the MV Hondius cruise ship highlight the risks of this rare infection and the need for diagnostic solutions like t...
NanoViricides’ NV-387 received Orphan Drug Designation for measles, offering incentives and supporting its development as a broad-spectrum antiviral a...
VolitionRx announces successful detection of nucleosomes in capillary blood from sepsis patients using a lateral flow finger-prick prototype, potentia...
Helus Pharma announced a partnership with TARA Mind and VETS to support recruitment for its Phase 3 PARADIGM trial of HLP003 in veterans with major de...
Ventripoint Diagnostics' VMS+ 4.0 system has been submitted for NMPA approval in China via an expedited green channel pathway, potentially acceleratin...
Formycon AG will publish its FY2025 results on April 22, 2026, and management will attend several international investor conferences in Q2 2026, highl...
Helus Pharma appointed Dr. Ken Kramer, a seasoned neuroscience medical affairs leader, as senior vice president of medical affairs, bolstering its eff...
GeoVax Labs advances its mpox/smallpox vaccine GEO-MVA toward a pivotal Phase 3 trial, aiming to address global orthopoxvirus vaccine supply constrain...
